EditorialOpen Access
Pitfalls and perils from FDA-approved germ-line cancer predisposition tests
Oncotarget · 2024
DOI: 10.18632/oncotarget.28677 ↗Kurz gefasst
Editorial in der Zeitschrift Oncotarget, 2024. Verfasst von Wafik S El-Deiry und 1 weiteren Autor:innen. Hauptthemen laut MEDLINE: United States Food and Drug Administration, Genetic Predisposition to Disease, Genetic Testing. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
United States Food and Drug AdministrationGenetic Predisposition to DiseaseGenetic TestingHumansUnited StatesNeoplasmsGerm-Line MutationGenetic CounselingDirect-To-Consumer Screening and Testing
Stichwörter der Autor:innen
cancer predispositiondirect to consumergermlinehereditary cancermarketing authorization
Zitieren
APA
El-Deiry, W. S., & Adashi, E. Y. (2024). Pitfalls and perils from FDA-approved germ-line cancer predisposition tests. Oncotarget. https://doi.org/10.18632/oncotarget.28677
Vancouver
El-Deiry WS, Adashi EY. Pitfalls and perils from FDA-approved germ-line cancer predisposition tests. Oncotarget. 2024. doi:10.18632/oncotarget.28677
BibTeX
@article{ElDeiry2024,
author = {El-Deiry, Wafik S and Adashi, Eli Y},
title = {Pitfalls and perils from FDA-approved germ-line cancer predisposition tests},
journal = {Oncotarget},
year = {2024},
doi = {10.18632/oncotarget.28677}
}
EUVIMED